There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Denmark's Prime Minister Mette Frederiksen had summoned business leaders after speaking on Wednesday with U.S.